Drug Trial Radar · NCT03718806
Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin
Last checked: Nov 20, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 3, 2018
Primary completion
Nov 12, 2018
Study completion Nov 12, 2018
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Quotient Sciences
- First posted
- Oct 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I, parallel, open-label, randomized, cross-over, single-center study with zoliflodacin administered as granules for oral suspension with or without food. It is planned to enroll 2 cohorts (Cohorts 1 and 2) of 24 subjects each (48 subjects in total), with the target of achieving data in 20 evaluable subjects per cohort. Single doses of zoliflodacin will be assessed within each cohort in a two period cross-over design. Each subject will receive one of the following regimens per period, depending on cohort, in a sequence according to the randomization schedule (per cohort, subjects will be randomized immediately before dosing in Period 1), separated by a minimum 4 day washout between each period. The actual length of washout period may change pending emerging PK data. Cohort 1: * Regimen A: 3 g zoliflodacin oral suspension; oral administration after an overnight fast * Regimen B: 3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast Cohort 2 * Regimen C: 4 g zoliflodacin oral suspension; oral administration after an overnight fast * Regimen D: 4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
Conditions
- Gonorrhea
Interventions
ZoliflodacinDrug
oral suspension; oral administration
high calorie, high fat breakfastOther
fasted/fed conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameter of zoliflodacin : CmaxTime frame: Day 3
- PK parameter of zoliflodacin : TmaxTime frame: Day 3
- PK parameter of zoliflodacin : AUCTime frame: Day 3
- PK parameter of zoliflodacin : T1/2Time frame: Day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.